Publications by authors named "P M Bailey"
Background: Coronary artery bypass grafting (CABG) provides superior long-term outcomes to percutaneous coronary intervention (PCI) for complex multivessel coronary artery disease (CAD). People with chronic kidney disease (CKD) have increased prevalence of multivessel CAD, but also increased surgical risk. We investigated whether CKD predicted real-world use of CABG, versus PCI, in patients revascularized for acute coronary syndrome (ACS).
View Article and Find Full Text PDFPurpose: The ESPAC4 trial showed that adjuvant chemotherapy with gemcitabine plus capecitabine (GemCap) produced longer overall survival (OS) than gemcitabine monotherapy. Subsequently, the PRODIGE24-CCTG PA.6 trial showed even longer survival for modified fluorouracil, folinic acid, irinotecan, and oxaliplatin (mFOLFIRINOX) than gemcitabine but had more restrictive eligibility criteria.
View Article and Find Full Text PDFBackground: Breast and cervical cancers pose significant health challenges for women globally, emphasizing the critical importance of effective screening programs for early detection. In Canada, despite the implementation of accessible healthcare systems, ethnic and racialized disparities in cancer screening persist. This study aims to assess ethnic and racialized disparities in breast and cervical cancer screening in Canada.
View Article and Find Full Text PDFArticle Synopsis
- A study analyzed data from over 10,000 patients with acute coronary syndrome (ACS) from 2010 to 2017 to explore the impact of reduced kidney function (eGFR) on treatment and mortality rates.
- It found that lower eGFR levels were strongly linked to a decrease in invasive treatments like coronary angiography; patients with eGFR <30 were significantly less likely to receive these procedures compared to those with higher eGFR.
- Additionally, there was a clear connection between lower eGFR and higher 30-day mortality rates, indicating that kidney function plays a critical role in treatment outcomes for ACS patients.
Background: Despite some recent advances, pancreatic ductal adenocarcinoma (PDAC) remains a growing oncological challenge. New drugs capable of targeting more than one oncogenic pathway may be one way to improve patient outcomes. This study characterizes the effectiveness of Metavert a first-in-class dual inhibitor of GSK3-β and histone deacetylase in treating PDAC as a single agent or in combination with standard cytotoxics.
View Article and Find Full Text PDF